Todd V. Brennan, MD, MS, FACS

Director, Transplant

Professor, Surgery

Todd V. Brennan, MD, MS, FACS

Comprehensive Transplant Center
8900 Beverly Blvd - 3rd Floor
Los AngelesCA





Todd V. Brennan, MD, MS, FACS

Director, Transplant

Professor, Surgery

  • Surgery-General Surgery
  • Surgery/Transplant Surgery

The research of Dr. Brennan focuses on how tissue injury causes inflammation and how this inflammation relates to rates of rejection of transplanted organs. Overall, the context in which transplanted organs are encountered by our immune cells is critical to determining the immune response against them. In the setting of tissue injury occurring during organ procurement, storage and transplantation, the immune system is alerted to the presence of tissue damage and initiates a response to this injury. In other words, the immune system recognizes danger signals released by the transplanted organ and can respond aggressively, attacking and damaging the organ. The goal of Dr. Brennan's research is to identify the molecules that create these signals and develop methods to prevent their release or block their recognition.

View NIH Biographical Sketch as a PDF

  • B.S., M.S. : UCLA, 1994
  • Medical School: Harvard Medical School, 1999
  • Internship: University of California, San Francisco Medical Center, 2000
  • Residency: University of California, San Francisco Medical Center, 2007
  • Fellowship: University of California, San Francisco Medical Center, 2009

View CV as a PDF

  • Clarence Gardner, M.D. Award, 2016
  • Health Scholar, Duke University School of Medicine, 2016
  • Career Development Award (NIAID), National Institutes of Health, 2012
  • Vanguard Award, American Society of Transplant Surgeons, 2010
  • Career Development Award in Liver Transplantation, American Association for the Study of Liver Diseases, 2010

Click here for a list of peer-reviewed publications.

  • Brennan TV, Lin L, Brandstadter JD, Rendell VR, Dredge K, Huang X, Yang Y. Heparan sulfate mimetic PG545-mediated antilymphoma effects require TLR9-dependent NK cell activation. J Clin Invest. 2016 Jan;126(1):207-219.
  • Brennan TV, Lin L, Huang X, Cardona DM, Li Z, Dredge K, Chao NJ, Yang Y. Heparan sulfate, an endogenous TLR4 agonist, promotes acute GVHD after allogeneic stem cell transplantation. Blood. 2012 Oct 4;120(14):2899-2908.
  • Brennan TV, Rendell VR, Yang Y. Innate immune activation by tissue injury and cell death in the setting of hematopoietic stem cell transplantation. Front Immunol. 2015 Mar 16;6:101.


Make an Appointment




Available 24 Hours A Day


Many of the physicians who have medical staff privileges to practice medicine at Cedars-Sinai Medical Center are independent physicians, and not employees or agents of the hospital. These independent physicians bill separately for their services. You should contact your physician to determine their status and billing practices.